Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 36

1.

Immunological function restoration with lopinavir/ritonavir versus efavirenz containing regimens in HIV-infected patients: a randomized clinical trial.

Torres B, Rallón NI, Loncá M, Díaz A, Alós L, Martínez E, Cruceta A, Arnaiz JA, Leal L, Lucero C, León A, Sánchez M, Negredo E, Clotet B, Gatell JM, Benito JM, Garcia F.

AIDS Res Hum Retroviruses. 2014 May;30(5):425-33. doi: 10.1089/AID.2013.0185. Epub 2014 Feb 10.

PMID:
24380397
[PubMed - in process]
2.

Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine.

Diaz-Brito V, León A, Knobel H, Peraire J, Domingo P, Clotet B, Dalmau D, Cruceta A, Arnaiz JA, Gatell JM, García F; DATEMPEP study group.

Antivir Ther. 2012;17(2):337-46. doi: 10.3851/IMP1955. Epub 2011 Nov 25.

PMID:
22293542
[PubMed - indexed for MEDLINE]
3.

Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial.

Miró JM, Manzardo C, Pich J, Domingo P, Ferrer E, Arribas JR, Ribera E, Arrizabalaga J, Loncá M, Cruceta A, de Lazzari E, Fuster M, Podzamczer D, Plana M, Gatell JM; Advanz Study Group.

AIDS Res Hum Retroviruses. 2010 Jul;26(7):747-57. doi: 10.1089/aid.2009.0105.

PMID:
20624069
[PubMed - indexed for MEDLINE]
4.

A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.

Martínez E, Arranz JA, Podzamczer D, Loncá M, Sanz J, Barragán P, Ribera E, Knobel H, Roca V, Gutiérrez F, Blanco JL, Mallolas J, Llibre JM, Clotet B, Dalmau D, Segura F, Arribas JR, Cosín J, Barrufet P, Casas E, Ferrer E, Curran A, González A, Pich J, Cruceta A, Arnaiz JA, Miró JM, Gatell JM; BICOMBO Study Team.

J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):290-7. doi: 10.1097/QAI.0b013e3181aa12d5.

PMID:
19398921
[PubMed - indexed for MEDLINE]
5.

Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.

Mallolas J, Podzamczer D, Milinkovic A, Domingo P, Clotet B, Ribera E, Gutiérrez F, Knobel H, Cosin J, Ferrer E, Arranz JA, Roca V, Vidal F, Murillas J, Pich J, Pedrol E, Llibre JM, Dalmau D, García I, Aranda M, Cruceta A, Martínez E, Blanco JL, Lazzari Ed, Gatell JM; ATAZIP Study Group.

J Acquir Immune Defic Syndr. 2009 May 1;51(1):29-36. doi: 10.1097/QAI.0b013e31819a226f.

PMID:
19390327
[PubMed - indexed for MEDLINE]
6.

A randomized trial comparing the efficacy and tolerability of two HAART strategies at two years in antiretroviral naive patients.

Mallolas J, Blanco JL, Pich J, Arnaiz JA, Peña JM, Dalmau D, de Lazzari E, Ochoa A, Vidal F, Ribas MA, Segura F, Pedrol E, Flores J, Cruceta A, Varea S, Miró JM, Martínez E, Gatell JM.

Rev Clin Esp. 2007 Oct;207(9):427-32.

PMID:
17915162
[PubMed - indexed for MEDLINE]
7.

Transmission of hepatitis C virus by discarded-needle injury.

Libois A, Fumero E, Castro P, Nomdedeu M, Cruceta A, Gatell JM, Garcia F.

Clin Infect Dis. 2005 Jul 1;41(1):129-30. No abstract available.

PMID:
15937781
[PubMed - indexed for MEDLINE]
Free Article
8.

Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection.

García F, Lejeune M, Climent N, Gil C, Alcamí J, Morente V, Alós L, Ruiz A, Setoain J, Fumero E, Castro P, López A, Cruceta A, Piera C, Florence E, Pereira A, Libois A, González N, Guilá M, Caballero M, Lomeña F, Joseph J, Miró JM, Pumarola T, Plana M, Gatell JM, Gallart T.

J Infect Dis. 2005 May 15;191(10):1680-5. Epub 2005 Apr 11.

PMID:
15838795
[PubMed - indexed for MEDLINE]
Free Article
9.

Long-term clinical follow-up, without antiretroviral therapy, of patients with chronic HIV-1 infection with good virological response to structured treatment interruption.

Florence E, García F, Plana M, Fumero E, Castro P, Lopez A, Cruceta A, Gil C, Arnedo M, Miró JM, Pumarola T, Gallart T, Gatell JM.

Clin Infect Dis. 2004 Aug 15;39(4):569-74. Epub 2004 Aug 3.

PMID:
15356824
[PubMed - indexed for MEDLINE]
Free Article
10.

Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3.

Plana M, Garcia F, Oxenius A, Ortiz GM, Lopez A, Cruceta A, Mestre G, Fumero E, Fagard C, Sambeat MA, Segura F, Miró JM, Arnedo M, Lopalcos L, Pumarola T, Hirschel B, Phillips RE, Nixon DF, Gallart T, Gatell JM.

J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):791-9.

PMID:
15213562
[PubMed - indexed for MEDLINE]
11.

Predictors of tonsillar tissue HIV-1 viral burden at baseline and after 1 year of antiretroviral therapy.

Navarrete P, Morente V, García F, Alós L, Arnedo M, Plana M, Gil C, Caballero M, Miró JM, Martínez E, Fumero E, Castro P, Blanco JL, Mallolas J, Blanch JL, Cruceta A, Mestre G, Pumarola T, Gallart T, Gatell JM.

Antivir Ther. 2003 Dec;8(6):635-7.

PMID:
14760898
[PubMed - indexed for MEDLINE]
12.

Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.

Martínez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, Knobel H, Riera M, Pedrol E, Force L, Llibre JM, Segura F, Richart C, Cortés C, Javaloyas M, Aranda M, Cruceta A, de Lazzari E, Gatell JM; Nevirapine, Efavirenz, and Abacavir (NEFA) Study Team.

N Engl J Med. 2003 Sep 11;349(11):1036-46.

PMID:
12968087
[PubMed - indexed for MEDLINE]
Free Article
13.

Genotypic and phenotypic resistance patterns in early-stage HIV-1-infected patients failing initial therapy with stavudine, didanosine and nevirapine.

Vidal C, Arnedo M, Garcia F, Mestre G, Plana M, Cruceta A, Capon A, Gallart T, Miro JM, Pumarola T, Gatell JM.

Antivir Ther. 2002 Dec;7(4):283-7.

PMID:
12553483
[PubMed - indexed for MEDLINE]
14.

Metabolic and immunological effects of antiretroviral agents in healthy individuals receiving post-exposure prophylaxis.

Garcia F, Plana M, Mestre G, Cruceta A, Martinez E, Miró JM, Mallolas J, Tuset M, Pumorola T, Gallart T, Gatell JM.

Antivir Ther. 2002 Sep;7(3):195-7.

PMID:
12487387
[PubMed - indexed for MEDLINE]
15.

Immunological and virological factors at baseline may predict response to structured therapy interruption in early stage chronic HIV-1 infection.

García F, Plana M, Mestre G, Arnedo M, Gil C, Miró JM, Cruceta A, Pumarola T, Gallart T, Gatell JM.

AIDS. 2002 Sep 6;16(13):1761-5.

PMID:
12218387
[PubMed - indexed for MEDLINE]
16.

[Thoughts about abuse of antibiotics in Spain:the individual against the collectivity].

Carné X, Cruceta A.

Med Clin (Barc). 2002 Apr 27;118(15):583-4. Spanish. No abstract available.

PMID:
12015948
[PubMed - indexed for MEDLINE]
17.

Immunologic reconstitution after 1 year of highly active antiretroviral therapy, with or without protease inhibitors.

Plana M, Martínez C, García F, Maleno MJ, Barceló JJ, García A, Lejeune M, Vidal C, Cruceta A, Miró JM, Pumarola T, Gallart T, Gatell JM.

J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):429-34.

PMID:
11981357
[PubMed - indexed for MEDLINE]
18.

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.

Martínez E, Blanco JL, Arnaiz JA, Pérez-Cuevas JB, Mocroft A, Cruceta A, Marcos MA, Milinkovic A, García-Viejo MA, Mallolas J, Carné X, Phillips A, Gatell JM.

AIDS. 2001 Jul 6;15(10):1261-8.

PMID:
11426070
[PubMed - indexed for MEDLINE]
19.

The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection.

García F, Plana M, Ortiz GM, Bonhoeffer S, Soriano A, Vidal C, Cruceta A, Arnedo M, Gil C, Pantaleo G, Pumarola T, Gallart T, Nixon DF, Miró JM, Gatell JM.

AIDS. 2001 Jun 15;15(9):F29-40.

PMID:
11416735
[PubMed - indexed for MEDLINE]
20.

Predictors of progression in chronically infected naive patients with plasma viraemia below 5000 copies/ml and CD4 T lymphocytes greater than 500 x 10(6)/I.

Garcia F, Plana M, Soriano A, Vidal C, Arnedo M, Gil C, Cruceta A, Pumarola T, Gallart T, Miro JM, Gatell JM.

AIDS. 2001 Jan 5;15(1):131-3. No abstract available.

PMID:
11192859
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk